4076
0
GSK TAKES 10% STAKE IN CUREVAC
Gsk takes 10% stake in Curevac.GlaxoSmithKline (GSK) will invest £ 130 million to purchase 10 percent of CureVac, Germany's biotechnology company.
Yazar: Tom Roberts
Yayınlanma: 20 Temmuz 2020 21:32
Güncellenme: 6 Kasım 2024 08:30
GSK TAKES 10% STAKE IN CUREVAC
GSK takes 10% stake in CureVac to bolster mRNA vaccine development. British pharmaceutical manufacturer GlaxoSmithKline (GSK) will invest £ 130 million ($ 163 million) to purchase 10 percent of CureVac, Germany's biotechnology company.
GSK will also initiate cooperation with this investment. It will be about develop up to five mRNA-based vaccines using the technology CureVac uses to develop the COVID-19 vaccine.
According to the company statement, CureVac's COVID-19 mRNA and rabies vaccine research and development are not included in the agreement.
CureVac announced in June that it would begin human trials in Germany for the COVID-19 vaccine.
The company, which is based in Tübingen and supported by the organization of the Bill & Melinda Gates Foundation, uses the RNA approach that BioNTech and its partner Pfizer, as well as Moderna, applies to developing a vaccine against coronavirus.
İLGİLİ HABERLER
European stocks soared and focus shifted to German retail sales after Powell's speech!
Forex Signal For TRY/USD: Inflation Slowdown in November.
Forex Signal For GBP/USD: Bullish Trend Still Not Breaking While Recovery Continues.
Forex Signal For EUR/USD: Starry US Data Points to Higher Fed Increases.
Forex Signal For BTC/USD: Downside Continues as Bitcoin Recovery Moves Less.
En Popüler Haberler
Yorum Yap
Yorumlar
Henüz yorum yapan yok! İlk yorumu siz yapın...